Release Date: 11-Jul-2025
The FDA granted accelerated approval to linvoseltamab-gcpt (Lynozyfic) in early July 2025, for the treatment of adults with relapsed or refractory multiple myeloma (MM), after its prior conditional approval by the European Medicines Agency (EMA) in April 2025. This bispecific antibody binds to B-cell maturation antigen (BCMA) and CD3 to stimulate T-cells, representing a key new therapy option for patients who have received several prior lines of therapy. Clinical trials, such as the LINKER-MM1 study, showed substantial efficacy, an objective response rate of 70%, and promising duration of response. The approval signifies an increasing trend in cancer drug development, especially in the development of bispecific antibodies for simultaneously targeting more than one pathway towards more effective precision therapies.
Download Report: https://www.kuickresearch.com/report-global-bispecific-antibody-market-size
Lynozyfic's approval is part of a broader shift in oncology towards bispecific antibodies as a whole, which are gaining traction for their potential to activate the immune system and target cancer cells more directly. These therapies, as well as others that target BCMA in multiple myeloma, are considered essential weapons to combat cancers that are resistant to traditional therapies. Lynozyfic's differentiated dosing regimen and robust efficacy make it a promising addition to the treatment landscape, offering hope to patients with few remaining options. This approval underscores the growing importance of bispecific antibodies in oncology, heralding a new era of cancer therapeutics.